CN105999217A - Composition for preventing and treating hyperuricemia as well as preparation method and application of composition - Google Patents
Composition for preventing and treating hyperuricemia as well as preparation method and application of composition Download PDFInfo
- Publication number
- CN105999217A CN105999217A CN201610457583.XA CN201610457583A CN105999217A CN 105999217 A CN105999217 A CN 105999217A CN 201610457583 A CN201610457583 A CN 201610457583A CN 105999217 A CN105999217 A CN 105999217A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- chinese medicine
- rhizoma atractylodis
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides composition for preventing and treating hyperuricemia. The composition comprises a traditional Chinese medicine extract and functional factors, wherein the traditional Chinese medicine extract comprises following raw materials: 3-30 parts of milkvetch roots, 3-30 parts of coix seeds, 3-30 parts of plantain herbs, 1-9 parts of atractylodes rhizomes, 1-12 parts of twotoothed achyranthes roots and 2-9 parts of papayas; the functional factors comprise 0.1-5 parts of skipjack tuna peptides. The invention further provides a preparation method of the composition. The composition for preventing and treating hyperuricemia adopts combination of traditional Chinese medicines including the milkvetch roots, the coix seeds, the plantain herbs, the atractylodes rhizomes, the twotoothed achyranthes roots and the papayas with the AC peptides, the medicines have a synergistic effect, and the uric acid reducing effect is greatly enhanced through combination of multiple ways including conditioning with the traditional Chinese medicines and uric acid generation inhibition and excretion promotion with the functional factors.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of compositions preventing and treating metabolic arthritis and its preparation method and application.
Background technology
Along with rich purine diet fatty, high and fructose dissipating fluid-retention material are at the change of interior modern way of life, blood in health check-up
Crowd's ratio that uric acid level increases is increasing.Epidemiological study shows, uric acid level and hyperuricemia over nearly 100 years
The change of prevalence has similar fashion trend to hypertension, obesity, diabetes and kidney disease.Nearly 10 years HUA of China suffer from
Sick rate averagely adds about 10 times.The disease that hyperuricemia is involved as a kind of multisystem, can directly result in gout, metabolic arthritis
Nephropathy, increases the weight of atherosclerosis, islets of langerhans opposing etc., and harm can not be ignored.
The drug main of western medical treatment hyperuricemia to include uricopoiesis processed and promote the big class of urate excretion two, often at present
Have probenecid, sulphinpyrazone, benzbromarone etc., these medicinal applications are often accompanied by the damage of serious hepatic and renal function.Metabolic arthritis
Mass formed by blood stasis belongs to the advantage disease kind of Chinese medicine, and early intervention can obviously reduce the gout caused by metabolic arthritis, metabolic arthritis nephropathy, the heart
Cerebrovascular sickness rate.
The traditional Chinese medical science thinks the card that hyperuricemia is deficiency in origin and excess in superficiality, and it occurs main cause natural endowment not enough, and exopathogenic factor wind and cold is damp and hot
Heresy dipping collaterals of human institute extremely, or overstrain, or cold and heat imbalance, or intemperance of taking food (excessive drinking, dyspepsia etc.) cause liver-spleen-kidney with
Qiactivity of triple energizer functional disorder, crystal's metabolism disorder, inverse in causing crystal, because of inverse mutagens.Caused by liver and kidney deficiency, dysfunction of the spleen in transportation be disease it
This, wind and cold is damp and hot, expectorant is turbid, blood stasis impatency meridians are mark.Hyperuricemia medication, based on damp eliminating, is held concurrently with heat clearing away, blood stasis dispelling, is mended
Gas.Present invention side entirely is with Radix Astragali spleen reinforcing lung qi, inducing diuresis to remove edema, and Semen Coicis invigorating spleen to remove dampness, relaxing muscles and tendons remove fraud, Herba Plantaginis clearing away heat and promoting diuresis,
Rhizoma Atractylodis are drying damp and strengthening spleen, Radix Achyranthis Bidentatae blood circulation and removing stasis dredging collateral, and Fructus Chaenomelis removing dampness to restore normal function of the stomach plays clearing away heat-damp and promoting diuresis, the effect of eliminating blood stasis and inducing menstruation altogether；Functional factor
Skipjack victory peptide can effectively suppress XOD enzymatic activity, reduces the generation of uric acid, improves renal epithelial cell urate transporter, strengthens urine
The excretion of acid.Chinese herbal medicine compounds with functional factor, the generation of joint effect uric acid and excretion pathway, makes uric acid recover to normal water
Flat, act on mitigation safely, it is to avoid " barbarous acid discharge ", " analgesia roughly ".
Summary of the invention
It is an object of the invention to provide a kind of compositions preventing and treating metabolic arthritis and application thereof, by Chinese herbal medicine and function because of
Son is compounding, and especially Chinese herbal medicine compounds with Skipjack victory peptide, reduces uric acid, even recovers normal purpose.
The first aspect of the invention is to provide a kind of compositions preventing and treating metabolic arthritis, and it comprises Chinese medicine extract and function
The factor, in parts by weight, described functional factor comprises Skipjack victory peptide 0.1-5 part, and the raw material of described Chinese medicine extract includes:
Radix Astragali 3-30 part, such as 5 parts, 8 parts, 12 parts, 15 parts, 20 parts, 22 parts, 25 parts, 28 parts etc.；Semen Coicis 3-30 part, such as 5 parts, 8
Part, 12 parts, 15 parts, 20 parts, 22 parts, 25 parts, 28 parts etc.；Herba Plantaginis 3-30 part, such as 5 parts, 8 parts, 12 parts, 15 parts, 20 parts,
22 parts, 25 parts, 28 parts etc.；Rhizoma Atractylodis 1-9 part, such as 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts etc.；Radix Achyranthis Bidentatae 1-12 part, such as 3
Part, 5 parts, 8 parts, 10 parts, 11 parts etc.；With Fructus Chaenomelis 2-9 part, such as 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts etc..
Wherein, described Chinese medicine extract is water extract, ethanol extract or the mixture of the two.
Preferably, described compositions also comprises the volatile oil of Rhizoma Atractylodis of 1-9 part.
Preferably, in parts by weight, the raw material of described Chinese medicine extract includes: Radix Astragali 6-20 part, Semen Coicis 6-20
Part, Herba Plantaginis 6-20 part, Rhizoma Atractylodis 2-6 part, Radix Achyranthis Bidentatae 3-8 part and Fructus Chaenomelis 4-6 part, described functional factor comprises Skipjack victory peptide 0.3-2
Part.
Preferably, in parts by weight, the raw material of described Chinese medicine extract includes: the Radix Astragali 9 parts, Semen Coicis 6 parts, Herba Plantaginis
Grass 9 parts, Rhizoma Atractylodis 3 parts, Radix Achyranthis Bidentatae 4 parts and Fructus Chaenomelis 5 parts, described functional factor comprises Skipjack victory peptide 1 part.
The second aspect of the invention is to provide the preparation of a kind of arbitrary composition as described in terms of the present invention is first
Method, it is characterised in that comprise the following steps:
Step 1, takes the raw material of Chinese medicine extract, extracts, obtain Chinese medicine extract；
Step 2, mixes Chinese medicine extract with functional factor and get final product.
Wherein, the extraction in step 1 can use: water extraction；Alcohol extracting method；Water carries rear alcohol extraction, united extraction thing；After alcohol extraction
Water carries, united extraction thing；Or raw material divides two parts, water carries and alcohol extraction respectively, is then combined with many extracting method such as extract
Extract.
Preferably, in the case of described compositions comprises the volatile oil of Rhizoma Atractylodis, extract the Rhizoma Atractylodis used by volatile oil permissible
Use the Rhizoma Atractylodis in the raw material of Chinese medicine extract, then step 1 is: takes the raw material of Chinese medicine extract, extracts, and obtains Chinese medicine and carries
Take thing and Rhzoma Atractylodis Lanceae volatile oil；Or the Rhizoma Atractylodis used by extraction volatile oil do not use the Rhizoma Atractylodis in the raw material of Chinese medicine extract, then walk
Rapid 1 is: takes Rhizoma Atractylodis and extracts its volatile oil；Take the raw material of Chinese medicine extract, extract, obtain Chinese medicine extract.
Wherein, the volatile oil extracting Rhizoma Atractylodis can use conventional essential oil extraction method, it is preferred to use vapor distillation
Method and/or supercritical carbon dioxide fluid extraction etc..
Compositions described in first aspect of the present invention or the preparation method described in second aspect of the present invention prepare
Compositions can be used for preventing and treating metabolic arthritis separately as active component, it is also possible to existing other preventing and treating metabolic arthritis activity
Components compatibility uses.So the third aspect of the invention is to provide a kind of preparation preventing and treating metabolic arthritis, its active component comprises
Arbitrary composition described in first aspect of the present invention or any preparation method described in second aspect of the present invention prepare
Compositions.
Wherein, described preparation can also comprise the active component of other preventing and treating metabolic arthritis.
Wherein, described preparation can be oral liquid, soft extract, syrup, granule, capsule, tablet, pill, powder
Or preparation capable of permeating skin etc..
Dosage form needs according to preparation, described preparation can also comprise pharmaceutically acceptable adjuvant.
The fourth aspect of the invention is to provide the arbitrary composition described in first aspect present invention or the present invention second
Any preparation described in compositions that any preparation method described in aspect prepares or third aspect present invention is anti-in preparation
Control the application in the goods (such as health product, medicine, food etc.) of metabolic arthritis.
The present invention prevents and treats the compositions of metabolic arthritis, with the Chinese medicines such as the Radix Astragali, Semen Coicis, Herba Plantaginis, Rhizoma Atractylodis, Radix Achyranthis Bidentatae, Fructus Chaenomelis with
Skipjack victory peptide is for combining, and all medicine synergism, from traditional Chinese medical science conditioning and functional factor suppression uricopoiesis and promotion excretion multipath
Combination, is greatly enhanced uric acid resisting effect.
Figure of description
Fig. 1 is renal tissues of rats URAT1, GLUT9, OAT1 albumen relative expression levels after feeding 28d in pharmacodynamic study experiment
Impact.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further illustrated, to be more fully understood that the present invention.
Embodiment 1
The present embodiment is mainly prepared from by the component of following weight parts proportioning:
The Radix Astragali 9 parts, Semen Coicis 6 parts, Herba Plantaginis 9 parts, Rhizoma Atractylodis 3 parts, Radix Achyranthis Bidentatae 4 parts, Fructus Chaenomelis 5 parts and Skipjack victory peptide 1 part.
Above-mentioned raw materials, Rhizoma Atractylodis coarse powder, use SFE-CO2Method, extracting pressure 30MPa, extraction temperature 50 DEG C, CO2Flow
25kg·h-1, extract 2h, obtain Rhzoma Atractylodis Lanceae volatile oil.Rhizoma Atractylodis medicinal residues mix with the Radix Astragali, Semen Coicis, Herba Plantaginis, Radix Achyranthis Bidentatae, Fructus Chaenomelis, add water
Extracting 2 times, add 12 times amount (weight) water for the first time, soak 0.5h, boil extraction 1.5 hours, second time adds 8 times amount (weight)
Water, boils extraction 1 hour, merges twice extracting solution；Extracting solution is filtered, concentrating under reduced pressure, temperature 65 DEG C-85 DEG C, vacuum-
0.03 ~-0.08Mpa, is concentrated into 1.2g/mL；It is spray-dried, injector temperature 160-175 DEG C, leaving air temp 95 DEG C, obtains spray drying
Powder；Add Skipjack victory peptide and relevant auxiliary materials, pelletize, send Rhzoma Atractylodis Lanceae volatile oil forth, i.e. obtain granule finished product.
Embodiment 2
The present embodiment is mainly prepared from by the component of following weight parts proportioning:
The Radix Astragali 10 parts, Semen Coicis 15 parts, Herba Plantaginis 9 parts, Rhizoma Atractylodis 6 parts, Radix Achyranthis Bidentatae 8 parts, Fructus Chaenomelis 2 parts and Skipjack victory peptide 1.6 parts.
Above-mentioned raw materials, Rhizoma Atractylodis coarse powder, use steam distillation, extract 6h, prepare Rhzoma Atractylodis Lanceae volatile oil.The Radix Astragali, Semen Coicis,
Herba Plantaginis, Radix Achyranthis Bidentatae, Fructus Chaenomelis mixing, 60% ethanol extraction 2 times, add 10 times amount (weight) 60% ethanol for the first time, soak 0.5h, backflow
Extracting 1.5 hours, second time adds 6 times amount (weight) 60% ethanol, reflux, extract, 1 hour, merges twice extracting solution；By extracting solution
Filter, concentrating under reduced pressure, temperature 55 DEG C-80 DEG C, vacuum-0.03 ~-0.08Mpa, be concentrated into without alcohol taste；Concentrated solution is female with Rhizoma Atractylodis
Liquid mixes, and is spray-dried, injector temperature 160-175 DEG C, leaving air temp 85 DEG C, obtains spray powder；Add Skipjack victory peptide and be correlated with
Adjuvant, pelletizes, sends Rhzoma Atractylodis Lanceae volatile oil, tabletting forth, i.e. obtain tablet finished product.
Embodiment 3
The present embodiment is mainly prepared from by the component of following weight parts proportioning:
The Radix Astragali 20 parts, Semen Coicis 20 parts, Herba Plantaginis 15 parts, Rhizoma Atractylodis 2 parts, Radix Achyranthis Bidentatae 5 parts, Fructus Chaenomelis 2 parts and Skipjack victory peptide 1.0 parts.
Above-mentioned raw materials, mixes Rhizoma Atractylodis, the Radix Astragali, Semen Coicis, Herba Plantaginis, Radix Achyranthis Bidentatae, Fructus Chaenomelis, 80% ethanol extract at low temperature 2 times,
Adding 10 times amount (weight) 80% ethanol for the first time, soak 0.5h, 60 DEG C are extracted 2.0 hours, and second time adds 8 times amount (weight) 80% second
Alcohol, 60 DEG C are extracted 1.5 hours, merge twice extracting solution.Concentrate under reduced pressure at low temperature, temperature 55 DEG C-70 DEG C, vacuum-0.03～-
0.08Mpa, is concentrated into without alcohol taste；Add Skipjack victory peptide and relevant auxiliary materials adds appropriate distilled water and dissolves, with Chinese medicine extraction concentrated solution
Mixing, add water constant volume, i.e. obtains oral liquid finished product.
Embodiment 4
The present embodiment is mainly prepared from by the component of following weight parts proportioning:
The Radix Astragali 5 parts, Semen Coicis 20 parts, Herba Plantaginis 15 parts, Rhizoma Atractylodis 3 parts, Radix Achyranthis Bidentatae 4 parts, Fructus Chaenomelis 4 parts and Skipjack victory peptide 0.5 part.
Above-mentioned raw materials, Rhizoma Atractylodis 85% ethanol extract at low temperature 2 times, add 12 times amount 85% ethanol for the first time, soak 0.5h, 55 DEG C carry
Taking 1.5 hours, second time adds 10 times amount 85% ethanol, and 60 DEG C are extracted 1.0 hours, merges twice extracting solution, concentrate under reduced pressure at low temperature,
Temperature 55 DEG C-65 DEG C, vacuum-0.02～-0.08Mpa, it is concentrated into without alcohol taste.The Radix Astragali, Semen Coicis, Herba Plantaginis, Radix Achyranthis Bidentatae, Fructus Chaenomelis
Mixing, extracting in water 2 times, add 20 times amount water for the first time, soak 0.5h, boil extraction 1.5 hours, second time adds 15 times amount water,
Boil extraction 1.5 hours, merge twice extracting solution, concentrating under reduced pressure, temperature 65 DEG C-85 DEG C, vacuum-0.03 ~-0.08Mpa is dense
It is reduced to 1.2g/mL.Merge Rhizoma Atractylodis concentrated solution and other Chinese crude drug concentrated solutions, add Skipjack victory peptide and relevant auxiliary materials, dissolve, fixed
Hold, i.e. obtain oral liquid finished product.
Embodiment 5
The present embodiment is mainly prepared from by the component of following weight parts proportioning:
The Radix Astragali 30 parts, Semen Coicis 10 parts, Herba Plantaginis 25 parts, Rhizoma Atractylodis 8 parts, Radix Achyranthis Bidentatae 10 parts, Fructus Chaenomelis 5 parts and Skipjack victory peptide 0.8 part.
The embodiment of the present invention respectively consists of commercial goods extract, adds customary adjuvant, by preparation process, prepares capsule
Agent, its uric acid resisting effect is notable.
Embodiment 6
The present invention is mainly prepared from by the component of following weight parts proportioning:
The Radix Astragali 6 parts, Semen Coicis 18 parts, Herba Plantaginis 20 parts, Rhizoma Atractylodis 9 parts, Radix Achyranthis Bidentatae 2 parts, Fructus Chaenomelis 8 parts, Skipjack victory peptide 4 parts.
In above example, each component is commercial goods, by conventional formulation technique (such as vapor distillation, supercritical
Carbon dioxide abstraction, water extraction or different quality mark ethanol alcohol extraction etc.), described on pharmaceutics multiple dose can be made
Type, such as oral liquid, capsule, tablet, powder or granule etc., does not limits.
The pharmacodynamic study of preventing and treating metabolic arthritis compositions
1 experiment material
Oteracil Potassium (Jinan, Shandong Province Cheng Huishuanda Chemical Co., Ltd.), compound method: every time accurately weigh 15g with distilled water
It is made into the suspendible emulsion of 15%；
Adenine (Guangzhou Qi Yun Bioisystech Co., Ltd)；
Uric acid reagent box (Fenghui Medical Science and Technology Co., Ltd., Shanghai)；
Blood urea nitrogen (Shanghai Kehua Bio-engineering Co., Ltd)；
Creatinine (CR) detection kit (Sekisui Medical Treatment Co., Ltd of Japan)；
Cholesterol (Chemical Reagent Co., Ltd., Sinopharm Group)；
Cholate (Chemical Reagent Co., Ltd., Sinopharm Group)；
Xanthine oxidase inspection testing cassete, xanthine dehydrogenase test kit (Bioengineering Research Institute is built up in Nanjing)；
Superoxide dismutase test kit (Bioengineering Research Institute is built up in Nanjing)；
Malondialdehyde Kit (Mei Lian bio tech ltd, Shanghai)；
Allopurinol (Guangzhou Bi Di pharmaceutcal corporation, Ltd), being configured to concentration with 0.1% CMC-Na is 2.7 mg/ml suspensions,
Preparation 3d consumption every time, 4 DEG C save backup.
The preparation of Chinese herbal medicine extract, reference example 1: Radix Astragali 540g, Semen Coicis 360g, Herba Plantaginis 540g, Rhizoma Atractylodis
180g, Radix Achyranthis Bidentatae 240g, Fructus Chaenomelis 300g, above-mentioned raw materials, Rhizoma Atractylodis are pulverized, and use SFE-CO2Method, extracting pressure 30MPa, extraction temperature
Spend 50 DEG C, CO2Flow 25kg h-1, extract 2h, obtain Rhzoma Atractylodis Lanceae volatile oil.Rhizoma Atractylodis medicinal residues and the Radix Astragali, Semen Coicis, Herba Plantaginis, Radix Achyranthis Bidentatae,
Fructus Chaenomelis mixes, extracting in water 2 times, adds 12 times amount water for the first time, soaks 0.5h, boils extraction 1.5 hours, and second time adds 8 times amount
Water, boils extraction 1 hour, merges twice extracting solution；Extracting solution is filtered, concentrating under reduced pressure, temperature 65 DEG C-85 DEG C, vacuum-
0.03 ~-0.08Mpa, is concentrated into 1.2g/mL；It is spray-dried, injector temperature 160-175 DEG C, leaving air temp 95 DEG C, obtains spray drying
Powder；Spray powder is pelletized, and sends Rhzoma Atractylodis Lanceae volatile oil forth, i.e. obtains Chinese herbal medicine extract.
2 laboratory animals
SPF level male SD rat (Zhongshan University's Experimental Animal Center, laboratory animal production licence number is: SCXK(Guangdong) 2011-
0029.The Quality of Experimental Animals quality certification number: 44008500002424).
3 experimental techniques
3.1 models are prepared, are grouped and dosage setting:
With adenine (100 mg kg-1·d-1, ig) and+oxygen potassium cyanate (1.5g kg-1·d-1, ig) and prepare metabolic arthritis rat mould
Type.SD male rat, adaptability is raised 5d, by body weight, animal is randomly divided into Normal group, model control group, allopurinol
Group, embodiment 1(L) group, embodiment 1(M) group, embodiment 1(H) group, Chinese herbal medicine extract group and Skipjack victory peptide group, often organize 10
Only.Relative medicine is given by packet situation.
Each sample dosage arranges and is shown in Table 1.Each dosage group sample is through dissolved dilution and is settled to suitable gavage volume.
Table 1 is by body weight conversion dosage
Based on body weight dose conversion, in allopurinol group, dosage is 27mg kg-1·d-1, embodiment 1(L) group dosage be
0.82g·kg-1·d-1, embodiment 1(M) group dosage be 1.64g kg-1·d-1, embodiment 1(H) group dosage be 3.28g kg-1·d-1, Chinese herbal medicine extract group dosage is 1.44g kg-1·d-1, Skipjack victory peptide group dosage is 0.2g kg-1·d-1, continuously
28d。
3.2 Testing index
3.2.1 blood serum metabolic index and the mensuration of xanthine oxidase
Before modeling, being administered 14d, after last is administered 1h, orbital venous plexus is taken a blood sample；Being administered 28d, after last is administered 1h, abdominal cavity is noted
Penetrating pentobarbital sodium (45mg kg-1) anesthesia, rat aorta takes blood, separate determination of serum uric acid (UA), creatinine (CR),
Blood urea nitrogen (BUN), T-CHOL (CHO), triglyceride (TG) and the level of xanthine oxidase (XOD).
3.2.2 hepatic tissue xanthine oxidase (XOD), the change of xanthine dehydrogenase (XDH) activity
It is administered 28d, after last administration after 1h, lumbar injection pentobarbital sodium (45mg kg-1) anesthesia, rat aorta takes
After blood, take liver tissues of rats block, be prepared as 100g L with the normal saline of pre-cooling-1Liver homogenate, detect in 36 hours.
Illustrate to measure liver homogenate XOD, XDH activity by test kit.
3.2.3 the mensuration of renal cortex GLUT9, OAT1, URAT1 protein expression
Take renal tissue to shred, liquid nitrogen grinding to unicellular, add 200ul RIPA lysate by every 10mg tissue and (contain
PMSF1mM), crack 30min, 4 DEG C of 12000rpm on ice and be centrifuged 15min, take supernatant ,-80 DEG C of Refrigerator stores, stand-by.Coomassie
Light blue G250 measures the OD value of protein solution, adjusts sample protein concentration and makes at same level (4 ~ 8 μ g μ l-1).Above-mentioned carry
The albumen taken uses 10% SDS-PAGE gel electrophoresis to separate, every hole loading 40 ~ 60 μ g total protein.Shift under the conditions of 70v
70min, by protein delivery to pvdf membrane, is placed in TBST rinsing 1 ~ 2 minute by albuminous coat；Add 5% defatted milk powder to close
1h is closed in fluid-tight.Indicate according to albumen Marker, with reference to an anti-description, by 1:1000(GLUT9), 1:500(OAT1, GAPDH,
URAT1) dilution proportion one resists；Pvdf membrane is put in an anti-solution, 4 DEG C of overnight incubation.TBST washs 3 times.With reference to two anti-theorys
Bright book, resists according to the two of 1:2500 dilution proportion horseradish peroxidase (HRP) labelling.By anti-to pvdf membrane and two incubated at room
1h；Put into TBST to wash 3 times.Use BeyoECLPlus chemical illuminating reagent, develop the color at dark, use X-ray tabletting, developer solution
And fixative solution develops a film.
3.2.4 data process and statistics
All experimental datas are all with representing.Using SPSS to carry out one factor analysis of variance, between two groups of means, difference uses t inspection.
3.3 result
3.3.1 before modeling and be administered 14, the change of 28d rat blood serum UA, CR, BUN, TG, CHO, XOD level be shown in Table 2 respectively ~
4。
As shown in Table 2, before modeling, each group rat blood serum UA, CR, BUN, TG, CHO, XOD level is close substantially, has no bright
Aobvious group difference (p > 0.05).
As shown in Table 3, being administered 14d, compare with Normal group, modeling group rat blood serum UA, BUN, CR and XOD level is equal
Notable rising (p<0.01), TG, CHO level slightly rises, but no difference of science of statistics (p>0.05).Compare with model control group,
Chinese herbal medicine group BUN level, allopurinol group serum UA, XOD level, embodiment 1(M) organize BUN, XOD level and embodiment 1
(H) group UA, BUN, XOD level all significantly reduce (p<0.05), remaining each index level change do not have significant difference (p>
0.05).Result shows, Oteracil Potassium+adenine modeling 14d, hyperuricemia rat model success, meanwhile, and uric acid level liter
Height causes injury of kidney to cause detection of glomeruli filtration function to decline, and creatinine, UAN level raise.It is administered 14d, allopurinol and enforcement
Example 1(H) organize the good reduction serum UA level of performance, the effect of suppression XOD activity.Embodiment 1(L), (M) two dosage groups give
Medicine 14d uric acid resisting effect is the most inconspicuous, but embodiment 1(M) organize the suppression XOD activity that performance is good.Embodiment 1(M), (H) group
And Chinese herbal medicine group BUN level reduces, prompting has the effect of protection renal function.
As shown in Table 4, it is administered 28d, compares with Normal group, model control group rat blood serum UA, BUN, CR and XOD water
Average notable rising (p < 0.01).Compare with model control group, allopurinol group serum UA, XOD level, embodiment 1(L),
(M), (H) group and Chinese herbal medicine group UA, BUN, CR, XOD level and Skipjack victory peptide UA, XOD level significantly reduce (p < 0.05).Table
Bright administration 28d, what allopurinol performance was good reduces serum uric acid level, the effect of suppression XOD activity, but causes metabolic arthritis
Renal function damage without reverse effect.Embodiment 1(L), (M), (H) group, Chinese herbal medicine group and Skipjack victory peptide group all show well
Reduce serum uric acid level, suppression XOD activity and protection renal function effect.
Reciprocal action character is analyzed, and is analyzed dosage group, Chinese herbal medicine group and Skipjack victory peptide group in embodiment 1, medium-height grass
Medicine uses with Skipjack victory peptide compatibility, reduces UA, XOD level, reverses injury of kidney and reduces CR, BUN level, and it is independent that effect is better than both
Use, and both exist the effect (dosage group in E embodiment 1 > E Chinese herbal medicine+E Skipjack victory peptide) of Synergistic.
Rat blood serum UA, CR, BUN, TG, CHO, XOD level before table 2 modeling (, n=10)
Table 3 is administered 14d rat blood serum UA, CR, BUN, TG, CHO, XOD level (, n=10)
Note: compare with Normal group:#p<0.01；Compare with model control group:*p<0.05。
Table 4 is administered 28d rat blood serum UA, CR, BUN, TG, CHO, XOD level (, n=10)
Note: compare with Normal group:#p<0.01；Compare with model control group:*p<0.05。
3.3.2 28d liver tissues of rats XOD, the change of XDH activity it are administered
Xanthine oxidase (XOD) and xanthine dehydrogenase (XDH) are two kinds of tautomeric form of xanthine oxidase fluidized dehydrogenation enzyme, are yellow
A member in fibroin family.The enzyme of two kinds of forms both participates in purine metabolism, is the key in purine metabolism and uric acid building-up process
Enzyme.The activity of suppression purine metabolism key enzyme, can effectively reduce serum uric acid level.As shown in table 5, with Normal group ratio
Relatively, XOD, XDH activity of model control group is notable raises (p < 0.05)；Compared with model group, allopurinol group, embodiment 1(L)
(M), (H) group XOD, XDH activity significantly reduce (p < 0.05), and embodiment 1(H) group with allopurinol group XOD activity without significantly
Difference (p > 0.05).Prompting embodiment 1 is by suppressing the effect of XOD, XDH activation plays uric acid resisting, and it suppresses XOD activity
Intensity is suitable with allopurinol.
Table 5 is administered 28d liver tissues of rats XOD, the change (, n=10) of XDH activity
Note: compare with Normal group:#p<0.05；Compare with model control group: * p < 0.05.
3.3.3 the impact of renal tissues of rats URAT1, GLUT9, OAT1 albumen relative expression levels after feeding 28d
Result is shown in that Fig. 1, URAT1, GLUT9 and OAT1 are the important urate transporters that kidney is responsible for that uric acid heavily absorbs, secretes.By
Fig. 1 is visible, and Normal group compares, and model control group is responsible for uric acid re-absorbed urate transporter URAT1, GLUT9 egg
White expression raises, and the urate transporter OAT1 protein expression level being responsible for uric acid secretion reduces；With model control group phase
Ratio, allopurinol, embodiment 1(L), (M), (H) there is reduction URAT1, GLUT9 protein expression level, raise OAT1 albumen table
Reach the effect of level.
The compositions using embodiment 2 ~ 6 to prepare carries out above-mentioned pharmacodynamic study, and result is with embodiment 1, Chinese medicine extract
Use with Skipjack victory peptide compatibility, UA, XOD, XDH level can be significantly reduced, reduce URAT1, GLUT9 protein expression level, reverse
Injury of kidney reduces CR, BUN level, raises OAT1 protein expression, and effect is better than both and is used alone, and produces Synergistic and makees
With.
Being described in detail the specific embodiment of the present invention above, but it is intended only as example, the present invention does not limit
It is formed on particular embodiments described above.To those skilled in the art, any equivalent modifications that the present invention is carried out and
Substitute the most all among scope of the invention.Therefore, the impartial conversion made without departing from the spirit and scope of the invention and
Amendment, all should contain within the scope of the invention.
Claims (10)
1. the compositions preventing and treating metabolic arthritis, it is characterised in that it comprises Chinese medicine extract and functional factor, according to weight portion
Number meter, the raw material of described Chinese medicine extract includes: Radix Astragali 3-30 part, Semen Coicis 3-30 part, Herba Plantaginis 3-30 part, Rhizoma Atractylodis 1-9 part,
Radix Achyranthis Bidentatae 1-12 part and Fructus Chaenomelis 2-9 part, described functional factor comprises Skipjack victory peptide 0.1-5 part.
Compositions the most according to claim 1, it is characterised in that described Chinese medicine extract includes: the water extract of the Radix Astragali and/
Or the water extract of ethanol extract, Semen Coicis and/or ethanol extract, the water extract of Herba Plantaginis and/or ethanol extract, the water extract of Rhizoma Atractylodis and/
Or the water extract of ethanol extract, Radix Achyranthis Bidentatae and/or ethanol extract and the water extract of Fructus Chaenomelis and/or ethanol extract.
Compositions the most according to claim 1, it is characterised in that it also comprises the volatile oil of Rhizoma Atractylodis of 1-9 part.
4. according to the compositions described in any one in claim 1-3, it is characterised in that in parts by weight, described in
The raw material of medicament extract includes: Radix Astragali 6-20 part, Semen Coicis 6-20 part, Herba Plantaginis 6-20 part, Rhizoma Atractylodis 2-6 part, Radix Achyranthis Bidentatae 3-8 part and
Fructus Chaenomelis 4-6 part, described functional factor comprises Skipjack victory peptide 0.3-2 part.
Compositions the most according to claim 4, it is characterised in that in parts by weight, described Chinese medicine extract former
Material includes: the Radix Astragali 9 parts, and Semen Coicis 6 parts, Herba Plantaginis 9 parts, Rhizoma Atractylodis 3 parts, Radix Achyranthis Bidentatae 4 parts and Fructus Chaenomelis 5 parts, described functional factor comprises
Skipjack victory peptide 1 part.
6. the preparation method of the compositions as described in any one in claim 1-5, it is characterised in that include following step
Rapid:
Step 1, takes the raw material of Chinese medicine extract, extracts, obtain Chinese medicine extract；
Step 2, mixes Chinese medicine extract with functional factor and get final product.
Preparation method the most according to claim 6, it is characterised in that described compositions comprises the volatile oil of Rhizoma Atractylodis,
Extract the Rhizoma Atractylodis in the raw material of the Rhizoma Atractylodis employing Chinese medicine extract used by volatile oil, then step 1 is: take Chinese medicine extract
Raw material, extracts, and obtains Chinese medicine extract and Rhzoma Atractylodis Lanceae volatile oil；Or
Extraction Rhizoma Atractylodis used by volatile oil do not use the Rhizoma Atractylodis in the raw material of Chinese medicine extract, then step 1 is: takes Rhizoma Atractylodis and extracts it
Volatile oil；Take the raw material of Chinese medicine extract, extract, obtain Chinese medicine extract.
Preparation method the most according to claim 7, it is characterised in that the volatile oil of Rhizoma Atractylodis use steam distillation and/
Or supercritical CO2Extraction obtains.
9. the preparation preventing and treating metabolic arthritis, it is characterised in that its active component comprises in claim 1-5 described in any one
Compositions or claim 6-8 in the compositions for preparing of preparation method described in any one.
10. preparation side described in any one in compositions described in any one or claim 6-8 in claim 1-5
The application in the goods of preparation preventing and treating metabolic arthritis of the preparation described in compositions that method prepares or claim 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610457583.XA CN105999217B (en) | 2016-06-22 | 2016-06-22 | Composition for preventing and treating hyperuricemia and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610457583.XA CN105999217B (en) | 2016-06-22 | 2016-06-22 | Composition for preventing and treating hyperuricemia and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105999217A true CN105999217A (en) | 2016-10-12 |
| CN105999217B CN105999217B (en) | 2020-02-21 |
Family
ID=57085742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610457583.XA Active CN105999217B (en) | 2016-06-22 | 2016-06-22 | Composition for preventing and treating hyperuricemia and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105999217B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109329930A (en) * | 2018-11-02 | 2019-02-15 | 广州市臻善科技有限公司 | A kind of composition and preparation method thereof for promoting uric acid to reduce |
| CN110881555A (en) * | 2019-11-07 | 2020-03-17 | 哈尔滨梵境园生物科技有限公司 | Dispersible candy tablet with dual-effect of lowering blood pressure |
| CN111704650A (en) * | 2020-06-29 | 2020-09-25 | 中食都庆（山东）生物技术有限公司 | Polypeptide with uric acid reducing effect, composition, compound preparation, preparation method and application |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425779A (en) * | 2002-12-31 | 2003-06-25 | 王全杰 | Super thin leather splitting method |
| CN104740451A (en) * | 2015-03-29 | 2015-07-01 | 福建省中医药研究院 | Traditional Chinese medicine composition for treating hyperuricemia and application of traditional Chinese medicine composition |
| CN105395577A (en) * | 2015-12-11 | 2016-03-16 | 汤臣倍健股份有限公司 | Composition capable of decreasing uric acid and preparation thereof |
-
2016
- 2016-06-22 CN CN201610457583.XA patent/CN105999217B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425779A (en) * | 2002-12-31 | 2003-06-25 | 王全杰 | Super thin leather splitting method |
| CN104740451A (en) * | 2015-03-29 | 2015-07-01 | 福建省中医药研究院 | Traditional Chinese medicine composition for treating hyperuricemia and application of traditional Chinese medicine composition |
| CN105395577A (en) * | 2015-12-11 | 2016-03-16 | 汤臣倍健股份有限公司 | Composition capable of decreasing uric acid and preparation thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109329930A (en) * | 2018-11-02 | 2019-02-15 | 广州市臻善科技有限公司 | A kind of composition and preparation method thereof for promoting uric acid to reduce |
| CN110881555A (en) * | 2019-11-07 | 2020-03-17 | 哈尔滨梵境园生物科技有限公司 | Dispersible candy tablet with dual-effect of lowering blood pressure |
| CN111704650A (en) * | 2020-06-29 | 2020-09-25 | 中食都庆（山东）生物技术有限公司 | Polypeptide with uric acid reducing effect, composition, compound preparation, preparation method and application |
| CN111704650B (en) * | 2020-06-29 | 2021-11-23 | 中食都庆（山东）生物技术有限公司 | Polypeptide with uric acid reducing effect, composition, compound preparation, preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105999217B (en) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1915292A (en) | Application of acetylcholine esterase inhibitor medication of Yidancao extractive as cholinomimetic | |
| CN102600423A (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN103301413A (en) | Traditional Chinese medicine composition for treating hyperlipemia and hyperglycemia | |
| CN107596241B (en) | A kind of anti-alcohol and liver-protection traditional Chinese medicine composition and its preparation method and application | |
| CN105999217A (en) | Composition for preventing and treating hyperuricemia as well as preparation method and application of composition | |
| CN103877438B (en) | Traditional Chinese medicine preparation for treating gout and production method thereof | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN104721467B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
| CN101953984B (en) | Medicinal composition for treating urarthritis, preparation method thereof, preparation thereof and use thereof | |
| CN103585504B (en) | Traditional Chinese medicine composition for treating sjogren syndrome and application | |
| CN103211996B (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN105267543A (en) | Chinese medical preparation for treating qi-stagnation and blood stasis type primary dysmenorrheal and chloasma | |
| CN101919985A (en) | Drug for treating fatty liver and preparation method and use thereof | |
| CN104548016A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hyperuricemia | |
| CN101590169A (en) | A kind of Chinese medicine composition that is used for the treatment of gout and preparation method thereof | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN1234407C (en) | Medicine for treating chronic prostatitis and its preparing method | |
| CN103169838B (en) | Medicine for treating hepatitis B | |
| CN102366480B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN1541691A (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN104645144A (en) | Traditional Chinese medicine preparation for treating nephritis and preparation method of traditional Chinese medicine preparation | |
| CN1272047C (en) | Medicine for invigorating liver and kidney to treat dryness of large intestine and constipation | |
| CN103432418B (en) | Chinese medicine composition of a kind of gout pain relieving and its production and use | |
| CN104069173B (en) | Treat pharmaceutical composition of liver diseases and preparation method thereof | |
| CN104189314B (en) | It is a kind of to treat the turbid pharmaceutical composition for checking card high fat of blood of phlegm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |